GlassScriptPhysician profile
Josie Vitale
NPI 1063641223
$9,763.27
in general payments reported to CMS, 2019-2025
27 companies · $5,041 in 2025
The $5,041 reported for 2025 was more than what 86% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $419 · 2021: $788 · 2022: $860 · 2023: $772 · 2024: $1,581 · 2025: $5,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Consulting Fee: $3,260 · Travel and Lodging: $575 · Education: $67.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.77 |
| Consulting Fee | $3,260.00 |
| Travel and Lodging | $575.29 |
| Education | $67.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,171.11 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $1,151.47 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $776.88 | 2020-2025 | |
| Csl Behring | $621.80 | 2019-2025 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $542.22 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Regeneron Healthcare Solutions, INC. | $451.22 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $428.80 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $188.39 | 2019-2025 | |
| Grifols USA, LLC | $178.31 | 2021-2025 | Xembify |
| Pfizer INC. | $169.59 | 2019-2025 | |
| Amgen INC. | $153.11 | 2022-2024 | Tezspire |
| Organon LLC | $120.56 | 2025 | Vtama |
| Shire North American Group INC | $117.89 | 2019 | |
| Pharming Healthcare, INC. | $99.11 | 2022-2023 | Ruconest |
| Abbvie INC. | $92.87 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $72.77 | 2020-2023 | Auvi-Q |
| Horizon Therapeutics Plc | $62.88 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $57.60 | 2022-2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $53.80 | 2023-2024 | Ryaltris |
| Hospira, INC. | $50.82 | 2025 | |
| Octapharma USA, INC. | $46.52 | 2024 | Octagam Immune Globulin (Human) |
| Optinose US, INC. | $43.11 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.90 | 2019-2022 | |
| Ionis Pharmaceuticals, INC. | $27.75 | 2025 | Donidalorsen |
| Teva Pharmaceuticals USA, INC. | $21.10 | 2021 | |
| Aimmune Therapeutics, INC. | $16.83 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josie Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.